| Literature DB >> 35053478 |
Shreya Chawla1,2, Vasileios K Kavouridis1,3, Alessandro Boaro1,4, Rasika Korde5, Sofia Amaral Medeiros6, Heba Edrees5, Elisabetta Mezzalira1,7, Francesco Sala4, Rania A Mekary1,5, Timothy R Smith1.
Abstract
Butterfly glioblastomas (bGBM) are grade IV gliomas that spread to bilateral hemispheres by infiltrating the corpus callosum. Data on the effect of surgery are limited to small case series. The aim of this meta-analysis was to compare resection vs. biopsy in terms of survival outcomes and postoperative complications. A systematic review of the literature was conducted using PubMed, EMBASE, and Cochrane databases through March 2021 in accordance with the PRISMA checklist. Pooled hazard ratios were calculated and meta-analyzed in a random-effects model including assessment of heterogeneity. Out of 3367 articles, seven studies were included with 293 patients. Surgical resection was significantly associated with longer overall survival (HR 0.39, 95%CI 0.2-0.55) than biopsy. Low heterogeneity was observed (I2: 0%). In further analysis, the effect persisted in extent of resection subgroups of both ≥80% and <80%. No statistically significant difference between surgery and biopsy was detected in terms of postoperative complications, although these were numerically larger for surgery. In patients with bGBM, surgical resection was associated with longer survival prospects compared with biopsy.Entities:
Keywords: butterfly glioblastoma; meta-analysis; prognosis
Year: 2022 PMID: 35053478 PMCID: PMC8773472 DOI: 10.3390/cancers14020314
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1PRISMA flow diagram of included articles.
Study characteristics of included articles.
| Reference | Country | Study | Study | Sample Size | Male Sex (%) | Mean Age (Years) | |
|---|---|---|---|---|---|---|---|
| Resection | Biopsy | ||||||
| Dziurzynski, 2012 | USA | Case series | 2000–2010 | 11 | 12 | 48% | 56.3 |
| Chaichana, 2014 | USA | Case series | 2007–2012 | 29 | 19 | 52% | NR |
| Dayani, 2018 | USA, Ireland | Case series | 2004–2014 | 14 | 25 | 59% | 57.8 |
| OpokuDarko, 2018 | Canada | Case series | 2004–2016 | 9 | 20 | 62% | 59.8 |
| Hall, 2019 | UK | Case control | 2011–2017 | 37 * | 64.9% | 62.7 * | |
| Franco, 2020 | Germany | Case series | 2005–2017 | 25 | 30 | 61.8% | 64 |
| Boaro, 2021 | USA, Italy | Case series | 2008–2018 | 26 | 36 | 51.6% | 64.3 |
* Sample size not stratified by treatment modality.
Comparison of pre-operative tumor volume, genetic profile, age, and sex between the resection and biopsy groups.
| Resection | Biopsy | |
|---|---|---|
| Mean pre-operative tumor volume in cm3 | 48.9 | 44.1 |
| IDH1/2 Mutation% (n/N) | 1.59% (1/63) | 2.63% (2/76) |
| MGMT Methylation% (n/N) | 34.4% (21/61) | 34.8% (24/69) |
| Mean age *, years | 58.3 | 62.8 |
| Sex (% Male) * | 57.3% | 65.2% |
* Data do not include Dziurynski and Hall as age and sex data were not stratified by intervention group.
Intervention and outcomes of included studies for all patients (surgery and biopsy).
| Reference | Receipt of Adjuvant Therapy (%) | Overall Survival (Median Months) | Extent of Resection (Median) | |
|---|---|---|---|---|
| Chemotherapy | Radiation | |||
| Dziurzynski, 2012 | 39.10% | 52.20% | 5.9 | 100% |
| Chaichana, 2014 | NR | NR | NR | 61.4% |
| Dayani, 2018 | 43.60% | 12.80% | 3.2 | 83.04% |
| OpokuDarko, 2018 | NR | NR | 3.3 | NR |
| Boaro, 2021 | 71.00% | 75.80% | 8.7 | 72.30% |
| Hall, 2019 | NR | NR | 3.3 | NR |
| Franco, 2020 | 52.5% | 34.6% | 8.3 | NR |
NR: not reported.
Figure 2Forest plots showing hazard ratios of surgery vs biopsy for overall survival. Each study is shown by the point estimate of the hazard ratio and 95% confidence intervals (extending lines). The diamond center represents the estimated pooled hazard ratio and the width represent its 95% confidence interval (labelled total).
Figure 3Forest plots showing hazard ratios of surgery vs. biopsy for overall survival stratified by EOR (≥80% vs. <80%).
Pooled incidence of complications (95% confidence intervals) † comparing surgery to biopsy.
| Complication | All | Surgery Subgroup | Biopsy Subgroup | Surgery vs. Biopsy | ||
|---|---|---|---|---|---|---|
| Motor | 7% (2%, 20%) | 11% (4%, 27%) | 5 | 1.3% (0%, 100%) | 3 | 0.33 |
| Speech and Language | 8% (4%, 15%) | 11% (5%, 22%) | 5 | 4% (0.3%, 37%) | 3 | 0.15 |
| Visuospatial | 0.4% (0%, 29%) | 1.59% (0.02%, 51.8%) | 5 | 0% (0%, 100%) | 3 | >0.99 |
| Cognition | 0.5% (0.01%, 30%) | 2% (0.04%, 49%) | 5 | 0% (0%, 100%) | 3 | >0.99 |
| Seizures | 10% (0.01%, 99%) | NR | NR | NR | NR | NR |
| Hydrocephalus | 7.4% (1.3%, 33%) | 7.84% (0.01%, 98%) | 2 | 7% (2%, 23%) | 1 | 0.85 |
| Total | 21% (14%, 31%) | 28% (18–41%) | 5 | 13% (4%, 37%) | 3 | 0.01 |
NR: not reported.
Post-operative complications compared by group.
| Reference | Resection | Biopsy |
|---|---|---|
| Dziurzynski, 2012 | NR | NR |
| Chaichana, 2014 | Motor deficit—3 (10%) | Motor deficit—3 (16%) |
| Dayani, 2018 | N—4/14 | NR |
| OpokuDarko, 2018 | N—2/10 | N—1/20 |
| Boaro, 2019 | N—10/26 with new post-operative deficits | NR |
| Hall, 2019 | 7/36 with postoperative complications | 5/36 with postoperative complications |
| Franco, 2020 | N—8/25 | N—5/30 |
NR: Not reported.
Quality assessment performed by authors using the questionnaire by Chan and Bhandari.
| Study | Clear Study Objectives/Question | Well Defined Study Protocol | Explicit Inclusion/Exclusion Criteria for Participants | Specified Time Interval for Patient Recruitment | Consecutive Patient Enrolment | Clinically Relevant Outcomes | Prospective Outcome Data Collection | High Follow-Up Rate | Overall |
|---|---|---|---|---|---|---|---|---|---|
| Dziurzynski, 2012 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Chaichana, 2014 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 |
| Dayani, 2018 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 |
| OpokuDarko, 2018 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 |
| Boaro, 2019 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 |
| Franco, 2020 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 |